

[REDACTED]

From: [REDACTED]
Sent: 18 June 2024 10:56
To: ECHA Restriction PFAS; [REDACTED]
Cc: [REDACTED]
Subject: For the ATD (maybe): Visit Dr. [REDACTED], May 14-17

Hi all,

[REDACTED] meeting with Dr [REDACTED] took place on 15 May.

There was no agenda for the meeting but according to the first message below, PFAS is one of [REDACTED] area of interest.

Below the whole exchange of emails for the organisation of this meeting with US Embassy. I don't know if this exchange should be added to the ATD documents or not.

Kind regards,
[REDACTED]

From: [REDACTED] state.gov>
Sent: Monday, May 6, 2024 11:46 AM
To: [REDACTED] <[REDACTED]@echa.europa.eu>
Subject: RE: Visit Dr. [REDACTED] May 14-17

CAUTION: This email originated from outside ECHA. Do not click links or open attachments unless you know the content is safe.

Check the email address of the sender. It is possible that the name of the sender is known to you (e.g. a colleague), but the actual sender is someone else.

Hieno juttu, monet kiitokset, [REDACTED] isäksi voit ilmoittaa [REDACTED] ja minut, yt Vesa

[REDACTED]
[REDACTED]
Email: [REDACTED] [nsf.gov](mailto:[REDACTED]@nsf.gov)
Phone: [REDACTED]
Organization: ITE
Title: [REDACTED]

[REDACTED]
[REDACTED]
U.S. Embassy Helsinki
[REDACTED] state.gov
Office: [REDACTED]
Cell: [REDACTED]

[REDACTED]
[REDACTED]
U.S. Embassy, Helsinki
Mob: [REDACTED]
Tel: [REDACTED]
e-mail: [REDACTED] [state.gov](mailto:[REDACTED]@state.gov)

From: [REDACTED] <[REDACTED]@echa.europa.eu>
Sent: Monday, May 6, 2024 10:50 AM
To: [REDACTED] [state.gov](mailto:[REDACTED]@state.gov)>
Subject: RE: Visit Dr. [REDACTED], May 14-17

Hei [REDACTED]

Buukataan siihen (15.5.) klo 13:30-14:30.
[REDACTED] alkaa sitten seuraava kokous klo 14:30.

Tuleeko [REDACTED] mukana muita?
Tarvitsisin kaikkien tulijoiden nimet (meidän security – reception kollegoille) niin kuin ne on kirjoitettu heidän passissaan tai ID-kortissa.

Yst.terv. [REDACTED]

From: [REDACTED] [state.gov](mailto:[REDACTED]@state.gov)>
Sent: Monday, May 6, 2024 10:34 AM
To: [REDACTED] <[REDACTED]@echa.europa.eu>
Subject: RE: Visit Dr. [REDACTED], May 14-17

CAUTION: This email originated from outside ECHA. Do not click links or open attachments unless you know the content is safe.

Check the email address of the sender. It is possible that the name of the sender is known to you (e.g. a colleague), but the actual sender is someone else.

Hei [REDACTED]

Palaisin vielä tuohon mahdolliseen keskiviikon tapaamiseen, täällä myös aikataulut vielä elävät. [REDACTED] in edellinen tapaaminen loppuu 13h, hän ennättäisi ECHA:aan 13h30, jos tämä sopii teille.

Yt [REDACTED]

From: [REDACTED] <[REDACTED]@echa.europa.eu>
Sent: Friday, May 3, 2024 10:40 AM
To: [REDACTED] [state.gov](mailto:[REDACTED]@state.gov)>
Cc: [REDACTED] <[REDACTED]@echa.europa.eu>
Subject: RE: Visit Dr. [REDACTED], May 14-17

Dear [REDACTED]

Please be informed that [REDACTED] welcomes to meet [REDACTED] at ECHA, and suggests a one-hour meeting.

We hope that one of the following times would be suitable for [REDACTED]

- On 14th May anytime between 11:00 and 15:00, or
- On 15th May 11:00-12:00

Regarding practicalities, you can find information about the access to our premises in the "Guide for visitors" on our website: [2faf6414-f868-65fd-1f6b-0237c70670c4 \(europa.eu\)](https://echa.europa.eu/2faf6414-f868-65fd-1f6b-0237c70670c4)

Kind regards,
[REDACTED]

[REDACTED]
[REDACTED]
Directorate of Risk Management

☎ [REDACTED]
✉ [REDACTED] echa.europa.eu
📍 echa.europa.eu
📍 P.O. Box 400, FI-00121 Helsinki, Finland



EMAS Registered

ISO 9001:2015 certified
ISO 14001:2015 certified



The above represents the opinion of the author and is not an official position of the European Chemicals Agency. This email, including any files attached to it, is intended for the use of the individual to whom it is addressed. If you have received this message in error, please notify the author as soon as possible and delete the message.

From [REDACTED] [state.gov](mailto:[REDACTED]@state.gov)>
Sent: Thursday, May 2, 2024 1:38 PM
To: [REDACTED] <[\[REDACTED\]@echa.europa.eu](mailto:[REDACTED]@echa.europa.eu)>
Cc: [REDACTED] [echa.europa.eu](mailto:[REDACTED]@echa.europa.eu)>
Subject: Visit Dr. [REDACTED], May 14-17

CAUTION: This email originated from outside ECHA. Do not click links or open attachments unless you know the content is safe.

Check the email address of the sender. It is possible that the name of the sender is known to you (e.g. a colleague), but the actual sender is someone else.

Dear [REDACTED]

Thank you very much for your collaboration during [REDACTED] visit to Finland.

The Embassy will be hosting National Science Foundation scientist, [REDACTED] the week of May 13. [REDACTED] is building a transatlantic network for sustainable semiconductor manufacture, focusing on developing PFAS alternatives.

█████ would appreciate an opportunity to visit ECHA. Please let me know if you have any availability for the week of May 13 (ideally May 14 or 15). We are happy to host you at the Embassy or meet you wherever is most convenient.

With kind regards, █████

https://www.nsf.gov/staff/staff_bio.jsp?lan=lmolnar&org=NSF&from_org=

Biography:

Dr. █████ is a scientist and entrepreneur with more than 20 years of experience in the life science and chemical industries, integrating █████ scientific research and engineering background with commercialization for startups, and international, government, and business environments. Currently, █████ is a █████ for the NSF Convergence Accelerator Program in the new Technology, Innovations, and Partnerships (TIP) Directorate at the U.S. National Science Foundation (NSF). The Convergence Accelerator is a relatively new (launched in 2019) organizational structure and activity within the NSF, designed to accelerate the transition of use-inspired convergence research into practice in areas of national importance. A guiding rationale of the Convergence Accelerator is that to achieve progress on scientific and societal challenges it is necessary to develop teams that can share expertise across research fields as well as with multiple partners and stakeholders, including the ultimate users of the research products. Previously, █████ was a Program Director in the NSF Engineering Directorate in the Division of Industrial Innovation and Partnerships where █████ managed a portfolio of Phase I and Phase II SBIR/STTR grants. █████ also served on the Working Group for the NSF Emerging Frontiers in Research and Innovation program (EFRI), which provides critical, strategic support of fundamental discovery at the frontiers of engineering research and education.

Prior to joining NSF, █████ was co-founder and CEO of Simpatica Medicine, Inc., an artificial intelligence precision medicine company based in San Francisco, California. █████ founded and advised numerous life science startup companies from top universities. █████ has also provided strategic consultancy to venture capital firms, public companies, non-profit institutes, and the federal government. █████ background includes positions as Managing Director in the Life Sciences Merchant Banking group and Venture Group at Burrill & Company, Executive in Residence at Momentum Biosciences, Program Officer for the National Cancer Institute in the Office of the Director (Center for Strategic Scientific Initiatives), and research and business development roles at Caliper Life Sciences, NASA Ames Research Center, and Rohm & Haas Co. █████ completed the University of Pennsylvania's Wharton Executive Management Program and holds a Ph.D. from the Program in Polymer Science and Technology (Materials Science and Chemical Engineering) from Massachusetts Institute of Technology and a B.S. in Chemistry (Biology) from the University of Pittsburgh (magna cum laude).

█████
█████
█████
U.S. Embassy, Helsinki

Mob: █████

Tel: █████

e-mail: █████@state.gov